ScholarWorks@Hanyang University: Sung, Yoon-Kyoung

Detailed Information

Sung, Yoon-Kyoung (성윤경)

서울 의과대학 (DEPARTMENT OF INTERNAL MEDICINE)

Research Area: 임상역학, 약물역학, 성과연구, Clinical epidemiology, Pharmacoepidemiology, Outcomes research

Tel 02-2290-9207
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Rheumatoid arthritis:52||rheumatoid arthritis:12||Systemic lupus erythematosus:11||Prevalence:10||systemic lupus erythematosus:10||Osteoarthritis:10||Arthritis:10||Osteoporosis:8||Safety:7||Rheumatoid:7||Epidemiology:7||Incidence:7||osteoarthritis:5||TNF inhibitor:5||s syndrome:5||Guideline:5||Mortality:5||Rheumatoid Arthritis:5||Ankylosing spondylitis:5||Treatment:5||rheumatoid:5||Glucocorticoids:5||Rheumatic diseases:4||arthritis:4||Quality of life:4||Sjogren&apos:4||Korea:4||Interstitial lung disease:4||Comorbidity:4||Gout:3||Therapeutics:3||Arthritis, rheumatoid:3||류마티스관절염:3||Arthritis, Rheumatoid:3||Knee:3||Etanercept:3||Adalimumab:3||Tuberculosis:3||Biologics:3||Biosimilar:3||Effectiveness:3||Biologic DMARDs:3||damage:3||Latent tuberculosis:3||Fatigue:3||Korean:3||Vertebral fracture assessment (VFA):2||safety:2||Registry:2||sesamoid bone:2||singlenucleotide polymorphism:2||acetaminophen:2||Immunosuppressive agents:2||Network metaanalysis:2||tomography:2||tramadol:2||Incidence rate:2||tuberculin skin test:2||Risk Factors:2||Fractures:2||Risk factor:2||Risk factors:2||Bleomycin:2||Inflammatory arthritis:2||Computed tomography:2||SARSCoV2:2||Discordance:2||Antiinflammatory agents:2||Coronavirus:2||Sacroiliac joint:2||Scleroderma:2||Corticosteroids:2||Osteporosis:2||#8208:2||Pain:2||Cancer:2||discontinuation:2||JAK inhibitors:2||Cardiovascular disease:2||Janus kinase inhibitor:2||Spine:2||Persistence:2||Korean Red Ginseng:2||Systematic review:2||Drug therapy:2||DAS28:2||incidence:2||Animal model:2||TNF blocker:2||latent tuberculosis infection:2||Polymyositis:2||DMARDs:2||Autoimmune inflammatory rheumatic disease:2||Antirheumatic agents:2||Pregnancy:2||Targeted therapy:2||Prognosis:2||Teriparatide:2||Denosumab:2||Magnetic resonance imaging:2||network metaanalysis:2||Depression:2||nonsteroidal:2||Tumor necrosis factor inhibitor:2||Malignancy:2||Expert consensus:2||Hip:2||polymorphism:2||RHEUMATOID ARTHRITIS:2||Uric acid:2||Hyperuricemia:2||Vaccine:2||Cohort:2||Cohort studies:2||remission:2||Recommendations:2||rheumatic disease:2||Immunization:2||s disease:2||HAQ:1||HAQDI:1||HEPATITIS B VIRUS:1||HLADRB1:1||HOUSEHOLD:1||Hallux valgus deformity:1||Hand:1||Health Assessment Questionaire:1||Health Assessment Questionnaire (HAQ):1||Health Care:1||Health Expenditure:1||Health assessment questionaire:1||Health assessment questionnairedisability index:1||Health services research:1||Healthrelated quality of life:1||Hemorrhage:1||Hindfoot:1||Hounsfield unit:1||Households:1||Hypouricemia:1||IL6:1||Idiopathic inflammatory myopathy:1||Immunosuppressant:1||Immunosuppression:1||Inflammation:1||Inflammatory Myopathy:1||Infliximab:1||Influencing factors:1||Influenza:1||Interferongamma release tests:1||Intervention threshold:1||Intestine:1||Isoniazid:1||JAK inhibitor:1||Janus Kinase Inhibitor:1||Janus kinase inhibitors:1||Jointpreserving surgery:1||Korean National Health Insurance reimbursement criteria:1||Korean population:1||Latent Tuberculosis Infection:1||Leflunomide:1||Lessebo effect:1||Liver neoplasm:1||Ludloff osteotomy:1||Lung:1||Lupus erythematosus:1||Lupus erythematosus systemic:1||Lupus erythematosus, Systemic:1||Lupus nephritis:1||MDP:1||Malignancies:1||Mapping:1||Matrix metalloproteinase:1||Medical Management:1||Medical care:1||Medical records:1||Medication persistence:1||Medication practices:1||Metabolic syndrome:1||Midfoot:1||Mobile applications:1||Multicenter clinical trial:1||NSAIDs:1||Neoplasm:1||Nonsteroidal:1||Nonsteroidal Antiinflammatory Drugs:1||Nonsteroidal antiinflammatory drugs:1||OCCULT INFECTION:1||Obesity:1||Opioids:1||Oral ulcer:1||Organ damage:1||Organizing pneumonia:1||Osteoporosisa:1||Osteoporotic fractures:1||Outcome assessment:1||Paraneoplastic syndromes:1||Patient dropouts:1||Patient education:1||Patient global assessment:1||Patient satisfaction:1||Patients:1||Patients reported outcomes:1||Peripheral arterial disease:1||Phenotype:1||Physician global assessment:1||Pill identification:1||Plasma cell:1||Pneumocystis jirovecii:1||Pneumomediastinum:1||Pneumonia:1||Polymyalgia Rheumatica:1||Polymyalgia rheumatica:1||Polyneuropathy:1||Positron emission tomography computed tomography:1||Postmarketing surveillance:1||Pregnancy outcome:1||Proportion:1||Psoriatic:1||Pulse wave velocity:1||QALY:1||Quality Indicators:1||Quality of Health Care:1||QuantiFERONTB Gold InTube test:1||QuantiFERONTB gold in tube test:1||Quantitative sensory testing:1||RA:1||RHEUMATIC DISEASES:1||Radiation:1||Radiography:1||Radiology:1||Raynaud&apos:1||Realworld evidence:1||Recurrence:1||Registries:1||Remission:1||Response rate:1||Rheumatic disease:1||Rheumatoid forefoot deformity:1||Rib:1||Risk:1||Risk assessment:1||Rituximab:1||Ro antibody:1||S DISEASE:1||SB4:1||SEX:1||SINGLENUCLEOTIDE POLYMORPHISMS:1||SKI306X:1||SLE:1||SNP:1||Self report:1||Seropositive rheumatoid arthritis:1||Severity of illness index:1||Side effects and adverse reactions:1||Simultaneous fracture:1||Sjogren syndrome:1||Sjogren's Syndrome:1||Sjogren's syndrome:1||Sleep:1||Spinal Fractures:1||Spinal fracture:1||Spinal fractures:1||Spondylitis:1||Standardised incidence ratio:1||Standardized incidence ratio:1||Switching:1||Symptomatic slowacting drugs for osteoarthritis:1||Systemic:1||Systemic Lupus Erythematosus:1||Systemic lupus erythematous:1||Systemic sclerosis:1||TNF biologics:1||TNF inhibitors:1||TNFalpha:1||TNFalpha blockers:1||TNFblocker:1||TNFα:1||TREX:1||TUMOR NECROSIS FACTORalpha BLOCKER:1||Tenosynovitis:1||Tofacitinib:1||Trabecular bone score:1||Treatment outcome:1||Treatment response:1||Trend:1||Tuberculin test:1||Tumor necrosis factor inhibitors:1||Tumor necrosis factoralpha:1||Tumor necrosis factoralpha inhibitor:1||Tumour necrosis factor inhibitor:1||Ulnar artery:1||Upadacitinib:1||Uric Acid:1||Usability:1||Utility:1||Vaccines:1||Validation study:1||Venous thromboembolism:1||Vertebra:1||Vertebral fracture:1||Vertebral fracture (VF):1||WTP:1||Whole Body Bone Scan:1||Willingness to Pay (WTP):1||active:1||acutephase protein:1||adultonset Still&apos:1||adverse event:1||analysis:1||ankylosing:1||antiinflammatory agents:1||antirheumatic agents:1||antirheumatic agents:1||aspirin:1||bDMARDs:1||bioinformatics:1||biologic DMARDs:1||biologic agent:1||biologic therapy:1||biological therapy:1||biologics:1||biomarkers:1||brain mapping:1||chondrocalcinosis:1||claims data:1||clinical manifestations:1||cohort study:1||corticosteroid:1||costbenefit analysis:1||costeffectiveness analysis:1||cyclophosphamide:1||depression:1||dermatomyositis:1||diagnostic codes:1||diseasemodifying antirheumatic drugs (biologic):1||doublebound dichotomous choice:1||drug utilisation:1||effect:1||effectiveness:1||efficacy:1||epidemiology:1||fasciitis:1||flare:1||focus score:1||followup:1||foot joints:1||genetic:1||genetics:1||hand:1||hand joints:1||hematologic malignancy:1||hospitalization:1||hydroxychloroquine:1||immunosuppressive agents:1||infection:1||interferongamma release assay:1||knee:1||lupus erythematosus:1||lupus flare:1||lupus nephritis:1||lupus pregnancy:1||malignancy:1||mavrilimumab:1||medical utilization:1||medication:1||memory disorders:1||miRNAs:1||microRNAs:1||minor salivary glands:1||mitochondrial DNA:1||myositis:1||n3 polyunsaturated fatty acids:1||nephritis:1||network meta&:1||non&:1||normal:1||opportunistic infections:1||osteoarthritis of knee:1||osteonecrosis:1||p21:1||patient health questionnaires:1||patientreported outcome:1||poly(ADPribose) polymerases:1||polymyositis:1||postmarketing surveillance:1||premature infants:1||primary Sjogren&apos:1||prospective study:1||quality of life:1||qualityadjusted life years:1||randomized controlled trial:1||reproducibility of results:1||risk factors:1||s Disease:1||s phenomenon:1||scoring methods:1||seropositivity:1||singlephoton emission computed tomography:1||solid malignancy:1||statistics:1||switching:1||systemic:1||tear:1||threshold:1||tofacitinib:1||transcriptome:1||treatment continuation:1||tumor necrosis factor inhibitor:1||validation:1||validation studies:1||waf1:1||건선 관절염:1||결핵:1||골다공증:1||대퇴골 골절:1||류마티스 질환:1||비스테로이드 소염제:1||사이클로옥시제나제 저해제:1||생물학적제제:1||안전성:1||알렌드로네이트:1||약물치료:1||인플릭시맙:1||임상연구:1||지불의사금액(WTP):1||지염:1||치료:1||코호트:1||표적요법:1||2010 ACR/EULAR Classification Criteria:1||ABCG2:1||ADMINISTRATIVE CLAIMS:1||ADULT ONSET STILL&apos:1||Abatacept:1||Additional Blood Pool Phase:1||Administrative claims healthcare:1||Adult Onset Still&apos:1||Aggrecanase:1||Alendronate:1||Algorithm:1||Algorithms:1||Amino acid:1||Amyloidosis:1||Analgesics:1||Anklebrachial index:1||AntiTNF drugs:1||Anticentromere antibody:1||Antinuclear antibody:1||Antiphospholipid antibody:1||Anxiety:1||Aphthous stomatitis:1||Arterial stiffness:1||Arteriography:1||Arthralgia:1||Asia:1||Atypical femoral fracture:1||Autoimmune Inflammatory Rheumatic Diseases:1||Autoimmune diseases:1||Avascular necrosis:1||Azathioprine:1||Back pain:1||Behçet&apos:1||Bent spine syndrome:1||Big data:1||Biologic DiseaseModifying Antirheumatic Drugs:1||Biologic agents:1||Biologic diseasemodifying antirheumatic drugs:1||Biological diseasemodifying antirheumatic drugs:1||Biological products:1||Bisphosphonate:1||Bisphosphonates:1||Bone:1||Bone Mineral Density:1||Bone Scintigraphy:1||Bone density:1||Bone mineral density:1||Bone scan:1||Bone scintigraphy:1||Bone turnover:1||CDKN1A:1||COMPLEMENTARY AND ALTERNATIVE MEDICINE:1||COVID19:1||COX Inhibitor:1||CRP:1||Camptocormia:1||Cartilage:1||Chondroitin:1||Chronic kidney disease:1||Chronic kidney failure:1||Claims data:1||Classification criteria:1||Clinical characteristics:1||Clinical research:1||Clinical study:1||Cohort study:1||Comparative effectiveness research:1||Comparative effectiveness study:1||Copy number variations:1||Cost effectiveness:1||Cost of illness:1||Cyclooxygenase inhibitors:1||Cyclophosphamide:1||Cyclosporine:1||DEPRESSION:1||Dactylitis:1||Data sources:1||Death:1||Dermatomyositis:1||Dermatomyositis/polymyositis:1||Diabetes mellitus:1||Diagnosis:1||Diagnostic Performance:1||Diagnostic imaging:1||Diffuse largecell lymphoma:1||Diphosphonates:1||Direct costs:1||Disease Management:1||Disease activity:1||Disease activity index:1||Disease activity score:1||Diseasemodifying antirheumatic drugs:1||Drug efficacy:1||Drug persistency:1||Drug retention rate:1||Drug treatment:1||Drug utilization:1||EQ5D:1||ESR:1||Early diagnosis:1||Efficacy:1||Elderly:1||Etoricoxib:1||EuroQol (EQ5D):1||FRACTURE:1||Fc gamma RECEPTOR:1||Femoral fracture:1||Filgotinib:1||Five dimensions:1||Fracture:1||Frequency:1||Functional disability:1||GLUCOCORTICOIDS:1||GWAS:1||Gastrointestinal diseases:1||Gender:1||Glucosamine:1||Granuloma:1||

RSS_1.0 RSS_2.0 ATOM_1.0

222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE